Monday, December 23, 2013
Among the patients with CLL trigger Ibrutinib and rituximab 95% response rate
University of Texas MD Anderson Cancer from the Center researchers United States blood of no. 55 times tournament report targeted therapy ibrutinib and antibody rituximab treatment of chronic lymphocytic leukemia patients meet the phase II clinical trials in high-risk almost everything.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment